Milciclib maleate

Drug Profile

Milciclib maleate

Alternative Names: PHA 848125C; PHA-125; PHA-848125; PHA-848125AC; TZLS-201

Latest Information Update: 31 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Nerviano Medical Sciences
  • Developer Nerviano Medical Sciences; Tiziana Life Sciences
  • Class 3-ring heterocyclic compounds; Amides; Antineoplastics; Piperazines; Pyrazolones; Quinazolines; Small molecules
  • Mechanism of Action CDC2 protein kinase inhibitors; Cyclin-dependent kinase 2 inhibitors; TrkA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Thymoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hepatocellular carcinoma; Thymoma
  • Phase I/II Glioma
  • Phase I Solid tumours
  • Preclinical Liver cancer
  • No development reported Mesothelioma

Most Recent Events

  • 31 Jul 2017 Chemical structure information added
  • 19 Jul 2017 Tiziana Life Sciences plans a phase IIb trial for Hepatocellular carcinoma (Combination therapy)
  • 12 Jun 2017 Phase-II clinical trials in Hepatocellular carcinoma (Inoperable/Unresectable, Metastatic disease, Recurrent, Second-line therapy or greater) in Turkey, Greece (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top